Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 788

1.

Serotonin receptors: their key role in drugs to treat schizophrenia.

Meltzer HY, Li Z, Kaneda Y, Ichikawa J.

Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72. Review.

PMID:
14642974
2.

Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.

Kuroki T, Nagao N, Nakahara T.

Prog Brain Res. 2008;172:199-212. doi: 10.1016/S0079-6123(08)00910-2. Review.

PMID:
18772034
3.

[Pharmacology of second-generation antipsychotics: a validity of the serotonin-dopamine hypothesis].

Kuroki T.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2004 Oct;24(5):257-64. Review. Japanese.

PMID:
15658501
4.

The role of serotonin receptors in the action of atypical antipsychotic drugs.

Meltzer HY, Massey BW.

Curr Opin Pharmacol. 2011 Feb;11(1):59-67. doi: 10.1016/j.coph.2011.02.007. Epub 2011 Mar 21. Review.

PMID:
21420906
5.

Atypical antipsychotics: mechanism of action.

Seeman P.

Can J Psychiatry. 2002 Feb;47(1):27-38. Review.

PMID:
11873706
6.

ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.

Li Z, Ichikawa J, Huang M, Prus AJ, Dai J, Meltzer HY.

Psychopharmacology (Berl). 2005 Dec;183(2):144-53. Epub 2005 Nov 9.

PMID:
16220333
7.

Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade.

Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN.

CNS Neurol Disord Drug Targets. 2006 Aug;5(4):445-52.

PMID:
16918396
8.

Receptor mechanisms in the treatment of schizophrenia.

Reynolds GP.

J Psychopharmacol. 2004 Sep;18(3):340-5. Review.

PMID:
15358977
9.

In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.

Meltzer HY, Huang M.

Prog Brain Res. 2008;172:177-97. doi: 10.1016/S0079-6123(08)00909-6. Review.

PMID:
18772033
10.

5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.

Li Z, Huang M, Prus AJ, Dai J, Meltzer HY.

Brain Res. 2007 Feb 23;1134(1):70-8. Epub 2007 Jan 4.

PMID:
17207474
11.

Role of serotonin in the action of atypical antipsychotic drugs.

Meltzer HY.

Clin Neurosci. 1995;3(2):64-75. Review.

PMID:
7583621
13.
15.

Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia.

Meltzer HY, Massey BW, Horiguchi M.

Curr Pharm Biotechnol. 2012 Jun;13(8):1572-86. Review.

PMID:
22283753
16.
17.

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE.

Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73.

PMID:
8935801
18.

Serotonergic mechanisms as targets for existing and novel antipsychotics.

Meltzer HY.

Handb Exp Pharmacol. 2012;(212):87-124. doi: 10.1007/978-3-642-25761-2_4. Review.

PMID:
23129329
19.

Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism.

Chung YC, Li Z, Dai J, Meltzer HY, Ichikawa J.

Brain Res. 2004 Oct 8;1023(1):54-63.

PMID:
15364019
20.

The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?

Bantick RA, Deakin JF, Grasby PM.

J Psychopharmacol. 2001 Mar;15(1):37-46. Review.

PMID:
11277607
Items per page

Supplemental Content

Write to the Help Desk